Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma (HCC): What’s New for This Old Treatment?
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 August 2021) | Viewed by 10555
Special Issue Editor
Université Grenoble Alpes, 38000 Grenoble, France.
Institute for Advanced Biosciences, Research Center Inserm U 1209 / CNRS 5309, 38700 La Tronche, France.
Interests: hepatocellular carcinoma; treatment; immunity; animal models; pre-clinical tests; liver transplantation
Special Issue Information
Dear Colleagues,
Transarterial chemoembolization has been used for many years for the treatment of hepatocellular carcinoma and it is one of the most used treatments in the world. Recent worldwide data show that TACE is associated with 40% of objective response after the first cure including 14% of complete response.
However, there is a lack of strong scientific evidence for efficacy and safety due to lack of large recent randomized control trials. There is still a debate on the real place of TACE in the HCC treatment arsenal. Immunotherapy in HCC opens new ways and opportunities.
This Special Issue will highlight the place of TACE in this new area.
Prof. Thomas Decaens
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- HCC
- TACE
- immunotherapy
- interventional radiologist
- liver transplantation